Desmond Nkrumah

Dr. Desmond Nkrumah

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
GKGustav Komlaga
Gustav Komlaga
AFArnold Donkor Forkuo
Arnold Donkor Forkuo
NSNadiatu Suleman
Nadiatu Suleman
Desmond NkrumahDesmond Nkrumah
Desmond Nkrumah
RNReinhard Isaac Nketia
Reinhard Isaac Nketia
SBSamuel Oppong Bekoe
Samuel Oppong Bekoe
The leaf of Theobroma cacao L. is used in traditional medicine in Ghana for the treatment of malaria, yet, with no scientific evidence of its antimalarial property in animals. It was, therefore, studied to validate the antimalarial property in Plasmodium berghei-infected mice. Infected mice were treated with an aqueous extract of T. cacao leaf at different doses of 100, 200, and 400mg/kg daily for four days. Parasitaemia was determined before treatment and 24 hours following the last dose of extract. The reduction in parasitaemia and ED50 and ED90 of the extract were determined. Body weight, rectal temperature, and daily mortality of mice were also recorded. The extract had ED50 and ED90 of 242.2029.38 and 351.0029.52mg/kg/day, respectively. Percentage parasitaemia suppression was significant for all doses. The extract at the maximum dose of 400mg/kg body weight had the highest parasitaemia suppression of 79.19; mean survival time of 24.002.19 days and median survival of 23 days; body weight increase of 3.820.59; and the lowest body temperature reduction of 0.790.11C. T. cacao leaf extract showed an antimalarial property in P. berghei-infected mice. This reinforces the justification for the use of the plant material in treating malaria in Ghana.

11 January 2024 in Heliyon
Verified
Journal Article
Open access
SKSolomon Appiah Kubi
Solomon Appiah Kubi
IAIsaac Kingsley Amponsah
Isaac Kingsley Amponsah
BTBernard Kofi Turkson
Bernard Kofi Turkson
EAEvelyn Asante-Kwatia
Evelyn Asante-Kwatia
Desmond NkrumahDesmond Nkrumah
Desmond Nkrumah
RDRita Akosua Dickson
Rita Akosua Dickson
Hyperlipidemia accounts for about 17 million deaths worldwide each year. High cost and side effects have limited the use of conventional anti-lipidaemic agents in some cases, majority of whom resort to traditional medicine. The current research focused on validating the safety and efficacy of a herbal product, ‘LIPO A’ used in the management of hyperlipidaemia. Induction of hyperlipidaemia was achieved by oral administration of 3 mL of cholesterol in coconut oil for 4 weeks in male Sprague Dawley rats with water available as 40 % sucrose. Subsequently, the animals were treated with 100, 200 and 400 mg/kg of the product ‘LIPO A’ for 4 additional weeks with atorvastatin as reference drug (at 2 mg/kg body weight). Blood samples were taken for serum biochemistry and atherogenic ratios were then calculated. 2,2-Diphenyl-1-Picrylhydrazyl (DPPH) scavenging assay, total antioxidant capacity, physicochemical and phytochemical analysis were also carried out using standard methods. Treatment resulted in a dose-dependent reduction in total cholesterol with maximum reduction of 46.01 % at 400 mg/kg compared to atorvastatin with 49.30 %. There were significant changes in the low-density lipoprotein cholesterol and high-density lipoprotein cholesterol (LDL-c/HDL-c) and Total Cholesterol (TC/HDL-c) ratios which measures the atherogenic and coronary risk indices respectively. Acute and subacute toxicity studies did not reveal any signs of toxicity. High Performance Liquid Chromatography (HPLC) fingerprint revealed six well resolved peaks with two prominent compounds with retention times 24.88 and 23.95 min, which could serve as quality control markers for the product. The herbal product showed considerable antihyperlipidemic and antioxidant actions in rodent models and lend credence to its use in traditional medicine for hyperlipidaemia.

10 November 2021
Verified
Book Chapter
Open access
PDF file
BTBernard Kofi Turkson
Bernard Kofi Turkson
AAAlfred Ofori Agyemang
Alfred Ofori Agyemang
Desmond NkrumahDesmond Nkrumah
Desmond Nkrumah
RNReinhard Isaac Nketia
Reinhard Isaac Nketia
MBMichael Frimpong Baidoo
Michael Frimpong Baidoo
MMMerlin Lincoln Kwao Mensah
Merlin Lincoln Kwao Mensah
Malaria is a public health challenge that requires prompt treatment for those infected to make a full recovery. Treatment of malaria infection is to be started as soon as a diagnosis is confirmed. Antimalarial medications are administered to prevent and also to treat malaria. The type of medication used and the duration of therapy is dependent on the type of malaria-causing plasmodium species, the severity of the symptoms, geographical area where malaria infection occurred and the medication used to prevent malaria and whether there is pregnancy. Treatment of malaria from public health perspective is to reduce transmission of the infection to others, by reducing the infectious reservoir and to prevent the emergence and spread of resistance to antimalarial medicines. Medications used in the treatment of malaria infection come from the following five groups of chemical compounds: quinolines and aryl amino alcohols, antifolate, artemisinin derivatives, hydroxynaphthoquinones and antibacterial agents. The treatment of malaria is not initiated until the diagnosis has been established through laboratory testing. Artemisinin-based Combination Therapy (ACTs) has been used for the treatment of uncomplicated malaria. ACTs are also to enhance treatment and protect against the development of drug resistance. IV artesunate is used in the treatment of severe malaria, regardless of infecting species.

28 November 2024
Verified
Book Chapter
Open access
PDF file
Desmond NkrumahDesmond Nkrumah
Desmond Nkrumah
RNReinhard Isaac Nketia
Reinhard Isaac Nketia
BTBernard Kofi Turkson
Bernard Kofi Turkson
GKGustav Komlaga
Gustav Komlaga
Malaria is an acute infection caused by the Plasmodium parasites, namely, P. falciparum, P. ovale., P. vivax, P. malariae, and P. knowlesii, in humans. The disease is spread through the bite of a mosquito carrying the parasite, which typically bites at night and lives at elevations lower than 1500 meters. Symptoms of the disease include fever, general body weakness and pains, headache, shivering, and vomiting among others which start manifesting about 6–9 days after a mosquito carrying the parasite bites a person. Africa, Eastern Europe, Asia, Central and South America, and the South Pacific are among the regions where malaria is transmitted. There has not been any malaria in Europe since 2015. The strategies used for malaria control include vector (mosquito) control, the use of insecticide treated nets, indoor residual spraying, and the use of antimalarial drugs and vaccines among others. The screening of potential antimalarial drugs usually employs in vitro and in vivo assays which evaluates the levels of parasitaemia following infection and drug treatment. The in vitro assays include Schizont counting on thick films, DNA dye intercalation assays, isotopic assays, and quantification of parasite proteins. The in vivo assays include the Peter’s four-day suppressive and Rane’s curative assays.

6 February 2025 in Scientific African
Verified
Journal Article
Open access
RNReinhard Isaac Nketia
Reinhard Isaac Nketia
Desmond NkrumahDesmond Nkrumah
Desmond Nkrumah
AFArnold Donkor Forkuo
Arnold Donkor Forkuo
EAEvelyn Asante-Kwatia
Evelyn Asante-Kwatia
FZFelix Kwame Zoiku
Felix Kwame Zoiku
GKGustav Komlaga
Gustav Komlaga

1 January 2023 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SASamuel Ansong
Samuel Ansong
Desmond NkrumahDesmond Nkrumah
Desmond Nkrumah
RNReinhard Isaac Nketia
Reinhard Isaac Nketia
SBSamuel Oppong Bekoe
Samuel Oppong Bekoe
ABAbena Amponsaa Brobbey
Abena Amponsaa Brobbey
GKGustav Komlaga
Gustav Komlaga
Sida cordifolia has been used to treat malaria in Ghana albeit without scientific evidence of antimalarial activity and safety. This work aimed to assess the antimalarial properties and acute toxicity of the aqueous leaf extract of S. cordifolia in murine models. Aqueous extract of the plant was analysed for both suppressive and curative antimalarial properties in chloroquine‐sensitive ANKA strains of rodent Plasmodium berghei‐infected mice. Acute toxicity evaluation was performed in rats according to the OECD 425 guidelines. The extract displayed antiplasmodial activity in vivo with ED50 of 117.49 ± 15.22 mg/kg and 144.84 ± 18.17 mg/kg in suppressive and curative studies, respectively. The highest % parasitaemia suppression exerted was 76.90 ± 0.64% and 61.50 ± 0.97%, respectively, in the suppressive and curative studies. Survival of infected mice treated with the extract was significantly prolonged. This was dependent on the dose of the extract but imperfectly related to the % parasitaemia suppression. Related antimalarial parameters including percentage hematocrit, changes in body weight, and temperature of experimental mice indicated alleviation of malarial symptoms of treated animals. The extract did not show toxicity in rats. Sida cordifolia L. has antimalarial properties, and was safe. It suppressed parasitaemia in both suppressive and curative studies, was not toxic to animals and prolonged the life of infected animals under treatment. This, therefore, justifies the traditional use of S. cordifolia for the treatment of malaria in Ghana.